Coiled Therapeutics PLC
COIL
Company Profile
Business description
Coiled Therapeutics PLC is an oncology company engaged in pursuing opportunities to find new therapies for cancer. The product pipeline of the company consists of AO-252, a novel TACC3 inhibitor currently in Phase I clinical trials in the USA; and STAT-6 siRNA programme for immunology indications. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Contact
85 Great Portland Street
First Floor
LondonW1W 7LT
GBRT: +44 2039188633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.10 | 59.30 | -0.66% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,678.44 | 236.76 | -0.91% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,446.98 | 306.75 | 0.52% |
| NZX 50 Index | 12,850.26 | 34.67 | -0.27% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,740.60 | 58.00 | -0.66% |
| SSE Composite Index | 4,069.44 | 23.81 | -0.58% |